Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, R&D and Chief Scientific Officer (CSO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, |
Shares
|
||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares (to cover tax on shares transferred in accordance with Long Term Incentive programme) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 319.80 | 22,000 | |||||
| d) | Aggregated information
|
22,000 shares |
||||
| e) | Date of the transaction | 2026-02-09 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com
|
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
|
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
|
| Max Ung +45 3077 6414 mxun@novonordisk.com
|
Sina Meyer +45 3079 6656 azey@novonordisk.com
|
| Alex Bruce +45 34 44 26 13 axeu@novonordisk.com
|
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com
|
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com
|
Company announcement No 09 / 2026
Attachment